sulfamethoxazole and Tuberculosis, Drug-Resistant
sulfamethoxazole has been researched along with Tuberculosis, Drug-Resistant in 2 studies
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients." | 5.43 | Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016) |
| " However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients." | 1.43 | Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Alsaad, N | 1 |
| Dijkstra, JA | 1 |
| Akkerman, OW | 1 |
| de Lange, WC | 1 |
| van Soolingen, D | 1 |
| Kosterink, JG | 1 |
| van der Werf, TS | 1 |
| Alffenaar, JW | 1 |
| Vilchèze, C | 1 |
| Jacobs, WR | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis[NCT01832987] | Phase 2 | 12 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Other Studies
2 other studies available for sulfamethoxazole and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tes | 2016 |
The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.
Topics: Anaerobiosis; Anti-Bacterial Agents; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculo | 2012 |